3SOF

Moving steady on up.
Head and Shoulders Bottom (Reversal) Pattern  and a,
Symmetrical Triangle (Continuation) Pattern

Biotechnology & Drugs  (6 new highs today)

52wk Range: 9.53 - 19.35

Volume: 538,856
Avg Vol (3m): 420,705

Technicals
MACD is Bullish
Stochastic is Bullish
Last Price Quote is:
9.65%above 13-day MA
12.52%above 50-day MA
RS Rating: 82 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/09/2006
Last Analyst Rating: Buy

Press Release Source: Keryx Biopharmaceuticals, Inc.


Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Friday November 10, 2:33 pm ET 
Presentations at Bear Stearns 2006 SMid-Cap Investor Conference and 2006 Annual Stanford Growth Conference to take place on Tuesday, November 14th


NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) today announced that the Company will be presenting at the Bear Stearns SMid-Cap Investor Conference and the 2006 Annual Stanford Growth Conference. Both presentations will take place in New York City on Tuesday, November 14, 2006.


Bear Stearns 2006 SMid-Cap Investor Conference: Corporate presentation will be delivered by Michael S. Weiss, the Company's Chairman and Chief Executive Officer, at 2:00 PM Eastern Time at the Bear Stearns World Headquarters. A live audio webcast of Mr. Weiss' presentation will be available at http://cc.talkpoint.com/BEAR002/111406a_cy/?entity=keryx . An archived version of the webcast will be available following the conclusion of the live presentation.

2006 Annual Stanford Growth Conference: Corporate presentation will be delivered by Ronald C. Renaud, Jr., the Company's Chief Financial Officer, at 8:30 AM ET at the St. Regis Hotel. A live audio webcast of Mr. Renaud's presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KERX&item_id=1417466. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

    Contact:
    Ronald C. Renaud, Jr.
    Chief Financial Officer
    212 531-5965
    [email protected]
--------------------------------------------------------------------------------
Source: Keryx Biopharmaceuticals, Inc.

A Fibonacci 61.8% retrace, looking for the bounce back to the upside.

Support @ $12.86...12.47...12.00
Resistance @ $13.50...13.99...14.66

52wk Range: 9.53 - 19.35
Volume: 287,476
Avg Vol (3m): 385,885

Technicals
Stochastic is Bullish

Last Price Quote is:
-2.52%below 13-day MA
-0.69%below 50-day MA
RS Rating: 90 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2007
Last Analyst Rating: Buy

Hello..... anybody out there ?

52wk Range: 9.53 - 19.35
Volume: 710,901
Avg Vol (3m): 380,524

Technicals
Percentage Gainer

Last Price Quote is:
4.31%above 13-day MA
5.55%above 50-day MA
RS Rating: 94 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2007
Last Analyst Rating: Buy

No more time ....
Today's closing chart

Technicals
Close Above the 13-day EMA

Last Price Quote is:
1.90%above 13-day EMA
4.76%above 50-day EMA
RS Rating: 62 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2007
Last Analyst Rating: Buy

Back above the 50/200-day MA
Looks to be closing in on a Golden Cross.......


52wk Range: 9.53 - 19.35
Volume: 976,671
Avg Vol (3m): 383,982

Technicals
Close Above the 50-day MA
Stochastic - Bullish
Percentage Gainer

Last Price Quote is:
2.26%above 13-day MA
4.14%above 50-day MA
RS Rating: 73 

Fundamentals
Key Data:
Market Cap (M): $545.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2007
Last Analyst Rating: Buy

TOP STORIES.......


Keryx Enters Into Licensing Agreement
With Japan Tobacco and Torii Pharmaceutical
Keryx Biopharmaceuticals (KERX) announced that it entered into a licensing
agreement with Japan Tobacco Inc. and Torii Pharmaceutical
Co., Ltd.,JT's pharmaceutical business subsidiary, under which JT and
Torii will hold the exclusive rights for the development and commercialization
of its hyperphosphatemia drug in Japan. The drug is currently in
phase II clinical development in the United States under the name of
"Zerenex(TM). The licensing arrangement calls for JT and Torii to pay
to Keryx up to $100 million in up-front license fees and payments upon
the achievement of pre-specified milestones, including up to $20 million
in up- front payments and near-term milestones. In addition, upon commercialization,
JT and Torii will make royalty payments to Keryx on net
sales of the drug in Japan. JT and Torii will be responsible for the future
development and commercialization costs in Japan.

REPORTS DATA SAFETY MONITORING BOARD EVALUATION: Keryx Biopharmaceuticals
(KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible
for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate
under development as a treatment for diabetic nephropathy, recently met to evaluate the data
from the ongoing Phase 3 trial. Following a complete review of all available safety and efficacy
data, the DSMC found no cogent reason to recommend alteration or termination of the Phase 3
trial. The DSMC raised no safety concerns regarding Sulonex or the trial.

updated chart look...

BreakOut...
Look for strong volume to push this on up.
The Golden Cross...Buy on Pull backs.

52wk Range: 0.09 - 0.57
Volume: 12,348,229
Avg Vol (3m): 1,063,190

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
99.25%above 13-day MA
169.94%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $20.12 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2009
Last Analyst Rating: Accumulate

Press Release Source: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
On Monday June 1, 2009, 8:30 am EDT


KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer

NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX - News) yesterday announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstract #4081, entitled, "Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer," was presented yesterday in a poster during the Gastrointestinal Cancer -- Colorectal session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida.

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, patients with 2nd or 3rd line metastatic colon cancer were randomized to receive capecitabine (Xeloda®), an approved drug for metastatic colon cancer, at a dose of 825 mg/m2 BID (total daily dose of 1650 mg/m2) on days 1-14 every 21 days, plus either perifosine or placebo at 50 mg daily. Treatment was continued until progression. The study enrolled a total of 38 patients, of which 35 patients were evaluable for response (20 patients on the capecitabine + perifosine arm and 15 patients on the capecitabine + placebo arm). The three patients not evaluable for response were all in the capecitabine + placebo arm; 2 patients were inevaluable due to toxicity (days 14, 46) and 1 patient was inevaluable due to a new malignancy on day 6.

The median prior treatment regimens was two, with prior treatment regimens as follows: 91% of the patients received prior FOLFIRI (Irinotecan + 5FU + Leucovorin); 74% prior FOLFOX (Oxaliplatin + 5FU + Leucovorin); 63% were previously treated with both FOLFIRI and FOLFOX; 77% received prior Avastin®; and 43% prior Erbitux®. Prior treatment with single agent capecitabine was excluded.

The primary endpoints of this study were to measure 1) Time to Progression (TTP); 2) Overall Response Rate (ORR), defined as the percentage of patients achieving a Complete Response (CR) or Partial Response (PR) by RECIST, and 3) Clinical Benefit Rate (CBR) defined as the percentage of patients on treatment for greater than three months with at least stable disease. Safety of perifosine + capecitabine vs. capecitabine + placebo in this patient population was evaluated as a secondary endpoint. Perifosine in combination with capecitabine was well tolerated with hand/foot syndrome (14%) and anemia (11%) as the highest reported grade 3/4 adverse events.

Best response and median time to progression of capecitabine + perifosine vs. capecitabine + placebo were as follows:


        Group                           SD > 12
                   N    CR   PR    ORR    Wks     CBR     Median TTP
                       N(%)  N(%)  N(%)   N(%)    N(%)      (wks)

    Capecitabine   20    1    3     4     11      15      28.9 weeks
     + Perifosine      (5%) (15%) (20%)  (55%)   (75%) {95% CI (13, 48.1)}
    Capecitabine
     + Placebo     15    0    1     1      5       6        11 weeks
                            (7%)  (7%)   (33%)   (40%) {95% CI (9, 15.9)}


Perifosine + capecitabine more than doubled time to progression vs. capecitabine + placebo with a statistically significant p-value = 0.0006. In addition, perifosine + capecitabine more than doubled the ORR and almost doubled the Clinical Benefit Rate vs. capecitabine + placebo.

Although not a primary endpoint in the study, overall survival was analyzed with results as follows:


              Group            Median Overall Survival*      % change
                                      (months)
    Capecitabine + Perifosine    22 {95% CI (12.1, NR)}    26% Increase**

    Capecitabine + Placebo     16.3 {95% CI (5.3, 17.1)}


    *  Survival calculated from date of randomization until date of death
       from any cause, whether or not additional therapies were received
       after removal from treatment

    ** As of May 2009, median overall survival in the perifosine +
       capecitabine patient group is ongoing with 10 of the 20 patients in
       this arm still alive.


Dr. Howard Burris, Chief Medical Officer and Director of Drug Development for the Sarah Cannon Research Institute, Nashville TN, an investigator involved in the Keryx-sponsored perifosine clinical program since 2004, remarked, "The results demonstrate that the addition of perifosine to capecitabine more than doubled time to progression and response rates, along with extending survival vs. capecitabine alone. Although not a large sample size, the data here is very interesting and next steps should be considered."

Ron Bentsur, Chief Executive Officer of Keryx, commented, "Patients with advanced metastatic colon cancer, who fail standard first and second line treatment, are truly in need of additional therapies. We are excited about the data as the combination of perifosine and capecitabine, two oral agents, appears to demonstrate superior clinical benefit over capecitabine alone in this advanced patient population. We will now explore plans to move this program forward in patients with advanced colorectal cancer." Mr. Bentsur added, "We wish to thank all the study investigators for their dedication to this clinical trial."

A copy of abstract #4081 is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/. A copy of the poster may be obtained by contacting the Company.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS - News; TSX: AEZ - News) in the United States, Canada and Mexico.

About Colon Cancer

According to the American Cancer Society, not counting skin cancers, colorectal cancer is the third most common cancer diagnosed in the United States. It is estimated that 106,100 people will be diagnosed with colon cancer, 40,870 people will be diagnosed with rectal cancer and approximately 50,000 deaths will be attributable to some form of colorectal cancer in 2009. Surgery is often the main treatment for early stage colon cancer. When colon cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colon cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have shown to increase survival rates for some stages of colorectal cancer. Currently, there are seven approved drugs for patients with metastatic colorectal cancer: 5-FU, capecitabine (Xeloda®), irinotecan (Camptosar®), oxaliplatin (Eloxatin®), bevacizumab (Avastin®), cetuximab (Erbitux®), and panitumumab (Vectibix®). Depending on the stage of the cancer, two or more of these types of treatment may be combined at the same time or used after one another.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.keryx.com. The information in our website and in the American Society of Clinical Oncology's website is not incorporated by reference into this press release and is included as an inactive textual reference only.


    KERYX CONTACT:
    Lauren Fischer
    Director, Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5962
    E-mail:  [email protected]

Quote from: setravis on May 27, 2009, 04:25:55 PM
BreakOut...
Look for strong volume to push this on up.
The Golden Cross...Buy on Pull backs.

Runaway Gaps...
Runaway gaps are also called measuring gaps, and are best described as gaps that are caused by increased interest in the stock. For runaway gaps to the upside, it usually represents traders who did not get in during the initial move of the up trend and while waiting for a retracement in price, decided it was not going to happen. Increased buying interest happens all of a sudden, and the price gaps above the previous day's close. This type of runaway gap represents an almost panic state in traders. Also, a good uptrend can have runaway gaps caused by significant news events that cause new interest in the stock. In the chart below, note the significant increase in volume during and after the runaway gap.

Runaway gaps can also happen in downtrends. This usually represents increased liquidation of that stock by traders and buyers who are standing on the sidelines. These can become very serious as those who are holding onto the stock will eventually panic and sell – but sell to whom? The price has to continue to drop and gap down to find buyers. Not a good situation.

The term measuring gap is also used for runaway gaps. This is an interpretation that is hard to find examples for, but it is a way of helping one decide how much longer a trend will last. The theory is that the measuring gap will occur in the middle, or half way, through the move.

Sometimes, the futures market will have runaway gaps that are caused by trading limits imposed by the exchanges. Getting caught on the wrong side of the trend when you have these limit moves in futures can be horrifying. The good news is that you can also be on the right side of them. These are not common occurrences in the futures market despite all the wrong information being touted by those who do not understand it, and are only repeating something they read from an uninformed reporter.

52wk Range: 0.09 - 0.82
Volume: 19,508,118
Avg Vol (3m): 1,453,000

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
169.41%above 13-day MA
302.61%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $33.53 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2009
Last Analyst Rating: Accumulate

BOOYA...

Biopharmaceuticals(KERX) seems like the big winner so far, the only ASCO stock up significantly....


Keryx Pharmaceuticals
Keryx blew up in March 2008 when its lead drug for diabetic nephropathy failed a pivotal phase III study. The setback sent the company's stock plunging below $1 where it has stayed ever since. Money became tight and the company was forced to restructure operations and cut back on the development of two remaining drugs. A new CEO took over Keryx's reins in May.
This weekend, Keryx presented mid-stage data from one of those remaining pipeline drugs. Perifosine, or KRX-0401, is an oral anti-cancer drug that targets the AKT pathway in cells, which when activated, promotes cell survival and resistance to chemotherapy. High levels of AKT are seen in many types of cancer and are often correlated with poor prognosis.

How it has performed since it was placed on my Watch List...

Keryx shares jump on positive Zerenex study
Keryx Biopharmaceuticals shares jump as kidney disease drug meets midstage study goal
On Monday June 8, 2009, 11:04 am EDT

NEW YORK (AP) -- Shares of Keryx Biopharmaceuticals Inc. jumped Monday after the company reported positive midstage safety results for its kidney disease drug.

The stock rose 34 cents, or 31.6 percent, to $1.42 in morning trading. Shares earlier reached $1.58, their highest point in the past 52 weeks.

The company is developing Zerenex as a treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage kidney disease. Those patients are on hemodialysis, which is used to remove waste products from the blood.

The drug candidate met its key safety goals in the study. Meanwhile, the midstage study results suggested that the drug is effective in regulating serum phosphorous levels, though the study is not designed to test for effectiveness.

Keryx is now in the process of developing a late-stage development program for the drug and is consulting with the Food and Drug Administration. The regulatory agency has already said the current studies are adequate to support late-stage clinical trials.